32-week results of the phase 3 DISCREET trial (289 randomised) in moderate to severe genital psoriasis: at week 32, genital PGA response was 51.8% with placebo then apremilast and 40.3% with apremilast throughout. Diarrhoea (25.4%), nausea and headache were common.
RCTn = 289 patients
Merola et al. Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis